#USA #Chicago #Clinical Trials #Semaglutide #Alzheimer's Association

Alzheimer's Association Statement on Semaglutide Study Results

On November 24, 2025, the Alzheimer's Association publicly expressed disappointment following the release of results from the Phase 3 clinical trials, evoke and evoke+, concerning Semaglutide, an oral medication aimed at treating early-stage Alzheimer's disease. The trials did not reveal any statistically significant reduction in the progression of Alzheimer's, a finding that raises concerns for ongoing research in this critical area.

Dr. Joanne Pike, the President and CEO of the Alzheimer's Association, summarized the sentiments of the association by stating that although the findings were not what they had hoped for, they contribute to the growing understanding of this severe and lethal disease. “Every study outcome is integral to enhancing our knowledge of Alzheimer’s and refining future clinical trials,” she noted, reflecting the association's long-standing commitment to advancing Alzheimer’s research.

The studies focused on evaluating the effectiveness of an oral Semaglutide pill in patients diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s, specifically stages 3 and 4 of the illness. While the treatment displayed improvements in Alzheimer's-related biomarkers, it did not successfully delay the disease's progression, highlighting critical gaps that remain in Alzheimer's care.

Dr. Maria C. Carrillo, the Chief Science Officer at the Alzheimer's Association, remarked that these findings will assist in refining their understanding of this class of drugs. “While this specific Semaglutide treatment didn’t show benefits in slowing Alzheimer’s, exploring this medication class further is essential, as it might work differently,” explained Carrillo.

The drive for innovative therapies remains strong within the association, as they lead efforts to explore varied approaches aimed at treatment and prevention. The pipeline of potential Alzheimer’s therapies shows promise; according to the latest annual review published earlier in 2025, there are currently 182 active clinical studies assessing 138 new drugs in development through the Alzheimer's Association.

With ongoing support from 'Part the Cloud’ program, the association seeks to expedite promising Alzheimer’s therapies into clinical study phases, advocating that effective Alzheimer treatment and prevention will likely require a personalized combination of several strategies.

Individuals diagnosed with early-stage Alzheimer’s have access to approved treatments and are strongly encouraged to discuss their options with healthcare providers. The Alzheimer's Association also offers resources for patients to inquire about participation in clinical studies, providing insights about ongoing trials through their trial-matching services available online.

As the association prepares to engage with these new findings, they anticipate discussing deeper insights during the upcoming Clinical Trials in Alzheimer's Disease (CTAD) conference in December. This continued dialogue underscores their commitment to fostering advancements in research, aiming towards an eventual cure for Alzheimer’s disease.

The Alzheimer's Association stands as a global volunteer health organization dedicated to care, support, and research for those impacted by Alzheimer’s. Their ultimate goal is to pave the way towards the end of Alzheimer’s and all forms of dementia by accelerating scientific research, promoting risk reduction, and enhancing the quality of care and support for patients and families affected by this debilitating disease. For more information, please visit alz.org or call 800.272.3900 for support and resources.